The U.S. Food and Drug Administration (FDA) is establishing guidelines to expedite the review of vaccines and drugs directed against the omicron variant of the coronavirus, The Wall Street Journal reported on Friday, citing people familiar with the matter.
Companies working on omicron-adapted vaccines are expected to meet standards similar to those required for booster authorization, according to the report.
The FDA did not immediately respond to a request for comment from Reuters.
Manufacturers of widely used vaccines against COVID-19, such as Moderna Inc and Pfizer Inc and his partner BioNTech, have said they are working on new doses against the variant, while also running tests to determine if their original injections work.
The variant has forced countries around the world to plan more stringent restrictions, threatening economic recovery and causing a sell-off in financial markets.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
